[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"IHU Strasbourg\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":233},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,47,76,107,132,159,185,206],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100567331","functional-personalised-and-integrated-profiling-of-biopsied-pancreatic-tumours-cancerprofile-by-fnb-100567331",false,"NCT06666803","Functional, Personalised and Integrated Profiling of Biopsied Pancreatic Tumours (CancerProfile by FNB)","Functional, Personalised and Integrated Profiling of Biopsied Pancreatic Tumours","Inclusion Criteria:\n\n* Adult patient over 18 years of age.\n* Patient undergoing echo-endoscopy with certainty\u002Fsuspicion of fine needle biopsy (EUS-FNB).\n* Suspicion of pancreatic lesion\n* Patient able to receive and understand information relating to the research protocol and to give consent.\n* Patient affiliated to the French social security system.\n\nExclusion Criteria:\n\n* Patient not programmed for endoscopy with certainty\u002Fsuspicion of fine needle biopsy (EUS-FNB).\n* Patient undergoing echo-endoscopy and presenting a high risk that may prevent EUS-FNB.\n* Patient with degenerated Intraductal papillary mucinous neoplasm (IPMN)\n* Patient with acute pancreatitis within 4 weeks prior to EUS\n* Pregnant or breast-feeding patient\n* Patient under court protection.\n* Patient under guardianship or curatorship.\n* Patient in a situation of social vulnerability.\n* Patient under legal protection or unable to express his\u002Fher opposition.","ALL","18 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"NA","Pancreatic ductal adenocarcinoma (PDAC) has the poorest prognosis of all digestive cancers due to lack of early diagnosis and limited response to treatment. Patient-derived organoid technology has become a mainstay of precision oncology, enabling personalised functional characterisation of tumours (e.g. treatment evaluation and drug screening). Initial research carried out as part of the Cancer Profile project has produced the first organoids from resected PDAC parts.\n\nOnly 15-20% of patients can benefit from surgical resection, which remains the only curative treatment. In contrast, most patients with PDAC undergo diagnostic fine-needle biopsies (FNB) using an echo-endoscopic procedure (EUS). The next step is therefore the reliable generation of organoids from limited quantities of biopsy material obtained by 'EUS-FNB'.\n\nThe aim of the study presented here is to validate these organoids on the basis of the following characteristics: (i) morphological and proliferative characteristics, (ii) recapitulation of the genetic characteristics of the original tumour, (iii) expression of tumour markers.",[26],"PDAC - Pancreatic Ductal Adenocarcinoma",[28,29,30,31,32,33],"PDAC","EUS","FNB","PDO","organoid","OCT","RECRUITING","2026-04-13",{"date":37,"type":38},"2026-04-16","ACTUAL",{"date":40,"type":38},"2025-01-27",{"date":42,"type":20},"2027-02",{"name":44,"class":45},"IHU Strasbourg","OTHER",2,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},"100627506","endoscopic-sleeve-gastroplasty-esg-prospective-trial-for-obesity-ego-trial-100627506","NCT07449520","Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)","Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity","Inclusion Criteria:\n\n* Patients aged 18 to 75 years.\n* Patients with a Body Mass Index (BMI) ≥ 30 kg\u002Fm².\n* Patients who have failed non-surgical weight loss interventions (diet, exercise, pharmacological therapy).\n* Patients not eligible for bariatric surgery or does not wish to undergo it.\n* Patients who can undergo general anesthesia.\n* Patients who are able to participate in all aspects of the study and agree to comply with all study requirements for the entire duration of the study.\n* Patients who are able to fully understand the study and are willing to give their consent to participate in the study.\n* Patients affiliated with the French social security system.\n\nExclusion Criteria:\n\n* Patients with contraindications to endoscopic gastroplasty\n* Patients with active peptic ulcer disease or significant gastroparesis\n* Patients with a history of bariatric, gastric, or esophageal surgery.\n* Patients who have started medication in the last 3 months that is known to cause weight gain.\n* Patients with a history of uncontrolled, poorly controlled, or suspected eating disorders or psychiatric illness.\n* Patients with unstable and precarious health, as determined and assessed by the investigator.\n* Patients who are pregnant, breastfeeding, or of childbearing age and not using effective contraception.\n* Patients who are currently excluded (as determined by a previous or ongoing study).\n* Patients under judicial protection.\n* Patients under guardianship, conservatorship or subject to any form of protective supervision","75 Years",{"count":56,"type":20},300,"OBSERVATIONAL","EGO-Trial is the first multicenter study in France which aims to evaluate the efficacy of Endoscopic Sleeve Gastroplasty (ESG) in patients with obesity. This project fills a critical national gap by providing real-world, multicentric data from diverse French healthcare settings, offering insight into the safety, efficacy, and variability of ESG practices across institutions\n\nThe project is expected to generate robust, multicentric clinical evidence on the safety and efficacy of ESG in patients with obesity within the French healthcare context.",[60],"Obesity",[60,62,63,64,65],"Endoscopic Sleeve Gastroplasty","Excess weight loss","Body Mass Index","Quality of Life","NOT_YET_RECRUITING","2026-02-27",{"date":69,"type":38},"2026-03-04",{"date":71,"type":20},"2026-03",{"date":73,"type":20},"2030-03",{"name":44,"class":45},10,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":21,"phases":86,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},"100584887","smart-intraoperative-reminder-to-implement-safety-principles-in-laparoscopic-cholecystectomy-100584887","NCT06895200","Smart Intraoperative Reminder to Implement Safety Principles in Laparoscopic Cholecystectomy","CVS-Notifier - Smart Intraoperative Reminder to Implement Safety Principles in Laparoscopic Cholecystectomy","CVS-Notifier","Inclusion Criteria:\n\n* Man or woman over 18 years old.\n* Patient presenting with benign gallbladder disease requiring an elective laparoscopic cholecystectomy.\n* Patient without contraindications to anaesthesia or laparoscopic cholecystectomy surgery.\n* Patients capable of understanding and providing their written consent to the study.\n* Patient affiliated to the French social security system.\n\nExclusion Criteria:\n\n* Patients presenting with malignant gallbladder disease requiring an elective laparoscopic cholecystectomy.\n* Pregnant or lactating patient.\n* Patient in exclusion period (determined by a previous or a current study).\n* Patient under guardianship or trusteeship.\n* Patient under the protection of justice or deprived of liberty.\n* Patient in situation of emergency.",{"count":85,"type":20},40,[23],"The Critical View of Safety (CVS) is universally recommended to prevent bile duct injuries in laparoscopic cholecystectomy. However, CVS is underutilized and bile duct injuries are not decreasing. The CVS-Notifier SaMD (Software as a Medical Device) reminds surgeons to verify the CVS before dividing the cystic duct, as recommended by guidelines. It is hypothesized that this systematic and timely reminder could improve the implementation of CVS without disturbing surgical workflows.",[89],"Cholecystectomy, Laparoscopic",[91,92,93,94,95,96,97],"Laparoscopic cholecystectomy","Gallbladder","Safety","Critical View of Safety","CVS","Bile Duct Injuries","BDI","2025-04-29",{"date":100,"type":38},"2025-04-30",{"date":102,"type":38},"2025-04-03",{"date":104,"type":20},"2026-05",{"name":44,"class":45},1,{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":21,"phases":116,"briefSummary":117,"conditions":118,"keywords":120,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":127,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":131,"locationsCount":106},"100577457","first-in-human-integrated-endoscopic-ultrasound-eus-navigation-system-clinical-study-100577457","NCT06798545","First-in-human Integrated Endoscopic Ultrasound (EUS) Navigation System Clinical Study","EZ-EUS1","Inclusion Criteria:\n\n* Man or woman over the age of 18 years old.\n* Patient having a EUS procedure for pancreas study planned within the frame of his or her clinical care.\n* Patient whom pre-operative imaging indicates one lesion, a suspicion of lesion, chronic pancreatitis or fatty pancreas.\n* Patient with a good definition on the CT scan done within the year to the EUS.\n* Patient able to receive and understand information related to the study and give his or her written consent.\n* Patient affiliated to the French social security system.\n\nExclusion Criteria:\n\n* Patient with altered anatomy of the upper digestive tract due to previous surgery.\n* Patient with known abnormal anatomy of the upper digestive tract.\n* Patient wearing a pacemaker.\n* Patients with comorbidities that may increase the risk of perforation.\n* Patient presenting, according to the investigator's judgment, a disease which may prevent participation in the procedures provided for by the study.\n* Patient with an ASA \\>3. Patient with ASA=3 must be validated by the Principal\n* Investigator (PI).\n* Patient unable to tolerate general anesthesia.\n* Patient with a body mass index (BMI) \\\u003C 18,5 and \\> 40.\n* Patient with weight variations \\>10% between the date on which the CT scan was performed and the date of the procedure.\n* Pregnant or lactating patient.\n* Patient in exclusion period (determined by a previous or a current study).\n* Patient under guardianship or trusteeship.\n* Patient under the protection of justice of deprives of liberty.\n* Patient in situation of emergency\n\nPerprocedure exclusion criteria\n\n• Patient in need of the balloon during the navigation will be excluded of the study (Experimental group)",{"count":115,"type":20},64,[23],"The complexity of the medical expertise required for endoscopic manipulation and image interpretation complicates the implementation of echo-endoscopy (or EUS for \"Endoscopic Ultrasound\").\n\nThe \"EZ-EUS\" system is designed to help the operator understand the orientation and the position of the probe tip in the patient. This system offers navigation similar to that of the Global Positioning System (GPS), but for EUS procedures. To achieve this, it uses a 3D model based on scanner imaging data recorded before the procedure.\n\nIn this study, the intended purpose of the \"EZ-EUS\" system is to help echo-endoscopy operators to easily identify and assess the pancreatic gland, and to facilitate the detection of any lesions.\n\nThe hypothesis is that, thanks to this tool, procedure times will be shortened, and the pancreas and its lesions will be fully imaged to facilitate their localization and characterization.",[119],"Pancreatic Diseases",[121,29,122,123,124,125,126],"endoscopic ultrasound","navigation","pancreatic disease","training","education","learning curve",{"date":100,"type":38},{"date":129,"type":38},"2025-01-28",{"date":71,"type":20},{"name":44,"class":45},{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":54,"enrollmentInfo":140,"targetDuration":4,"studyType":21,"phases":142,"briefSummary":143,"conditions":144,"keywords":146,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":106},"100435074","gastric-recalibration-after-endoscopic-sleeve-gastroplasty-100435074","NCT04945473","Gastric Recalibration After Endoscopic Sleeve Gastroplasty","Assessment of the Impact of Endoscopic Gastric Revision by Application of Additional Sutures on Weight Loss After Endoscopic Sleeve Gastroplasty in Obese Patients","ESG-IRM","Inclusion Criteria:\n\n* Patients aged 18 to 75\n* Patients with morbid obesity (BMI≥ 30 with comorbidities or\\> 40)\n* Patients with obesity for more than 2 years\n* Failure of medical treatment of obesity\n* Patients who may benefit from general anaesthesia\n* Patient able to participate in all aspects of the study and that agree to comply with all study requirements, for the duration of the study. This includes the availability of reliable transportation and sufficient time to attend all follow-up visits.\n* Patient able to fully understand the study and ready to give consent to participate to the study.\n* Patient affiliated to the French social security system\n\nExclusion Criteria:\n\n* Patient with a contraindication to perform an ESG\n* Patient with a history of previous bariatric, gastric or esophageal surgery.\n* Patient who initiated medical therapy within the last 3 months, with evidence of weight gain.\n* Patient with an uncontrolled, poorly controlled, or suspected history of eating disorders or psychiatric illness.\n* Patient with unstable and precarious state of health, as determined and assessed by the investigator.\n* Patient who is pregnant, breastfeeding or of childbearing age and without effective contraception.\n* Patient in exclusion period (determined by a previous or ongoing study)\n* Patient under legal protection\n* Patient under guardianship or curatorship\n* Patients with a BMI less than 30 at 6 months after ESG. These patients will not be candidate for revision regardless of the randomization group.\n* Patients with a contraindication to MRI may be included in the study and will follow the \"No Imaging\" study design.",{"count":141,"type":20},100,[23],"Endoscopic sleeve gastroplasty (ESG) is a technique used for bariatric surgery, with results comparable to conventional surgery, in order to treat morbid obesity. It has also less risks of complications, and it is not an irreversible technique. It can be repeated overtime, regarding the evolution of the gastroplasty. There is little data in the literature on the effectiveness of endoscopic \"revision\". This study will assess the benefits and costs of a revision during the follow-up endoscopy.",[145],"Morbid Obesity",[147,148,149,150,151],"obesity","Endoscopy","ESG","Gastric emptying","Revision procedure",{"date":153,"type":38},"2025-05-01",{"date":155,"type":38},"2021-07-13",{"date":157,"type":20},"2026-09",{"name":44,"class":45},{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":21,"phases":168,"briefSummary":169,"conditions":170,"keywords":173,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":179,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":106},"100418907","fluorescence-image-guided-foregut-surgery-100418907","NCT04734821","Fluorescence Image Guided Foregut Surgery","Prospective Study on the Contribution of Fluorescence in the Guidance of Lymphadenectomy and in Peroperative Evaluation of Pre-anastomotic Tissue Perfusion in Laparoscopic Esogastric Oncologic Resections","FOREGUT","Inclusion Criteria:\n\n* Man or woman over 18 years old.\n* Patient with resectable primitive esophageal or gastric cancer confirmed by biopsy without distant metastases\n* Patient with no contraindications to anaesthesia and performance of esophageal and\u002For gastric surgery\n* Patient able to receive and understand information related to the study and give written informed consent.\n* Patient affiliated to the French social security system.\n\nExclusion Criteria:\n\n* Patient undergoing emergency surgery (hemorrhage, occlusion or perforation).\n* Presence of distant metastasis\n* Patient at risk of allergy to indocyanine green or to other fluorescent compounds\n* Pregnant or lactating patient.\n* Patient in exclusion period (determined by a previous or a current study).\n* Patient under the protection of justice.\n* Patient under guardianship or trusteeship.\n* Patient deprived of liberty",{"count":19,"type":20},[23],"A high number of resected lymph nodes is an independent prognostic factor for improved survival after esophagectomy or gastrectomy for cancer. The quality of the lymphadenectomy is operator-dependent, as is the evaluation of the vascularization of the digestive structures that are anastomosed to restore digestive continuity after esophago-gastric resection. The aim of the study is to evaluate the impact of Indocyanine Green (ICG) and near infra-red (NIR) fluorescence imaging guidance in terms of number of lymph nodes resected and quality of gastrointestinal tract anastomoses in esophagogastric cancer surgery.",[171,172],"Esophageal Cancer","Gastric Cancer",[174,175,176,177,178],"Esophageal cancer","Gastric cancer","Lymphadenectomy","Complications","Anastomosis",{"date":153,"type":38},{"date":181,"type":38},"2021-04-01",{"date":183,"type":20},"2026-03-31",{"name":44,"class":45},{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":192,"enrollmentInfo":193,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":194,"conditions":195,"keywords":196,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":200,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":106},"100328340","endoscopic-gastric-tubulization-100328340","NCT03554902","Endoscopic Gastric Tubulization","Endosleeve","Inclusion Criteria:\n\n* Patients scheduled for an endoscopic gastric tubulization in the Nouvel Hôpital Civil, Strasbourg, France","65 Years",{"count":56,"type":20},"Endoscopic gastric tubulization is currently proposed in the Digestive Surgery Department of the Nouvel Hôpital Civil, Strasbourg, France, to adult patients with morbid obesity. The procedure is performed using the CE marked endoscopic suture device Overstitch (Apollo Endosurgery, Austin, Tx. USA). It is standard practice since October 2016.\n\nThe objective of this study is to prospectively collect data of patients who underwent an endoscopic gastric tubulization, from last visit before procedure to 2 years after procedure. These data are usually collected during medical consultations and will enable the evaluation of weight loss, quality of life and comorbidities improvement, reproducibility and durability of the technique.",[145],[197,198,199],"Endoscopic gastric tubulization","Weight loss","Quality of life",{"date":153,"type":38},{"date":202,"type":38},"2018-06-08",{"date":204,"type":20},"2028-06",{"name":44,"class":45},{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":212,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":214,"targetDuration":216,"studyType":57,"phases":4,"briefSummary":217,"conditions":218,"keywords":219,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":106},"100271349","an-evaluation-of-the-outcomes-of-bariatric-surgery---a-cohort-study-100271349","NCT02811900","An Evaluation of the Outcomes of Bariatric Surgery - a Cohort Study","An Evaluation of the Outcomes of Bariatric Surgery - a Cohort Study Internal Hernia After Laparoscopic Roux-en-Y Gastric Bypass: an Evaluation of the Impact on the Postoperative Course and a Quality of Life Case-control Study","ChirBar","Inclusion Criteria:\n\n* patient \\>18 years old\n* BMI \\> 35 kg\u002Fm²\n\nExclusion Criteria:\n\n* Incapacity of giving an informed consent",{"count":215,"type":20},10000,"30 Years","A prospective bariatric database was carried out in the Department of Digestive and Endocrine Surgery at the University Hospital of Strasbourg, France, starting in January 1996. All potential candidates for obesity surgery were prospectively registered in the database. Patients were informed by the bariatric surgeon of the prospective database, and of the possibility of utilizing personal data for research purpose after anonymization.\n\nA case-control study was performed, to compare the quality of life (QoL) of patients treated for internal hernia (IH group) with the QoL of patients with an uncomplicated course after Roux en Y gastric bypass (Uncomplicated RYGB group).",[145],[220,221,222,223,224],"obesity surgery","Roux en Y gastric bypass","sleeve gastrectomy","excess weight loss","quality of life","2017-11-08",{"date":227,"type":38},"2017-11-09",{"date":229,"type":4},"1996-01",{"date":231,"type":20},"2026-12",{"name":44,"class":45},""]